Clinical Trials Logo
  1. Home
  2. Muscle Invasive Bladder Cancer
  3. NCT03832673

Pembrolizumab-Epacadostat Combination to Treat Muscle-invasive Bladder UrotheLIAl canceR: PECULIAR Study — PECULIAR  

Muscle-invasive Bladder Cancer Clinical Trial

Official title:
PECULIAR: An Open Label, Monocenter, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab and Epacadostat, Preceding Radical Cystectomy, for Patients With Muscle-invasive Bladder Cancer.

Clinical Trial Summary

An open label, monocenter, single-arm, phase 2 study of neoadjuvant pembrolizumab and epacadostat, preceding radical cystectomy, for patients with muscle-invasive bladder cancer.

Clinical Trial Description

An open label, monocenter, single-arm, phase 2 study ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03832673
Study type Interventional
Source Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Contact
Status Withdrawn
Phase Phase 2
Start date May 22, 2019
Completion date May 22, 2019
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04687254 - Gender-related Characteristics of Bladder Cancer Treatment
Recruiting NCT04099589 - Neoadjuvant Treatment of Upper Urinary and Muscular Invasive Bladder Urothelial Carcinoma Phase 2
Active, not recruiting NCT03661320 - A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer Phase 3
Active, not recruiting NCT02462239 - Impact of Positron Emission Tomography (PET) Imaging in Muscle-invasive Urothelial Carcinoma of the Bladder Staging N/A
Recruiting NCT04660344 - A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Bladder Cancer Who Are ctDNA Positive Following Cystectomy Phase 3
Recruiting NCT06373055 - Prediction of Therapeutic Response to Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer Patients Using Spatial Transcriptomics
Terminated NCT03234153 - Neoadjuvant Immunotherapy With Durvalumab and Tremelimumab for Bladder Cancer Patients Ineligible for Cisplatin Phase 2
Recruiting NCT05945108 - Brazilian Reality of Urinary Bladder Cancers - BRA-BLADDER
Recruiting NCT06362330 - Multi-parametric MRI in Patients of Bladder Cancer
Completed NCT04209114 - A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That May Have Invaded The Muscle Wall of the Bladder and Who Cannot Get Cisplatin, A Type of Medicine Given To Treat Bladder Cancer Phase 3
Active, not recruiting NCT00808639 - Dose-Dense MVAC With Pegfilgrastim Support in Subjects With Muscle-Invasive Urothelial Carcinoma Phase 2
Not yet recruiting NCT06335667 - mpMRI Compared to Diagnostic TURBT in Patients With Suspected Muscle-Invasive Bladder Cancer Objectives N/A